First Asian Clinical Trials Confirm Viagra is Well-tolerated and Safe

ข่าวทั่วไป Tuesday October 13, 1998 10:47 —PRESS RELEASE LOCAL

Bangkok--Oct 13--Pfizer
Pfizer recently announced the results of the first Asian clinical trials of Viagra (sildenafil citrate). The Asian results, released at a Viagra launch event for Thai doctors, are consistent with the results of extensive US clinical studies and show that Asian men suffering from erectile dysfunction (ED) reported improvement in achieving and maintaining erections. The trials concluded that sildenafil is an effective and well-tolerated oral treatment for men with ED of broad-spectrum etiology.
The clinical trials, called ASSESS (ASian Sildenafil Efficacy and Safety Study), were conducted in Thailand, Hong Kong, Indonesia, Malaysia, Singapore and the Philippines and involved 690 patients participating at 23 sites across Asia. Patients selected for the trials were men aged 18 years and over who had been suffering from ED for at least six months and were involved in a stable relationship with a female partner. In Thailand, the ASSESS study was conducted at 4 university hospitals and involved 125 men suffering from ED.
The ASSESS trials were segmented according to a multi-country approach, with Malaysia, Singapore and the Philippines comprising ASSESS-1 and Thailand, Hong Kong and Indonesia comprising ASSESS-2. ASSESS-3 involving Taiwan is currently ongoing. Results from the ASSESS-2 trials, including Thailand, demonstrate that 81 percent of men with ED reported improved erections after 12 weeks of Viagra treatment, versus 28 percent on placebo. Similar figures were obtained from the ASSESS-1 trials. Side effects experienced by patients were mild and transient in nature. The major conclusion derived from the ASSESS study is that Viagra is an effective and well-tolerated oral treatment for Asian men suffering from ED.
“The safety and efficacy results demonstrated in Pfizer’s large-scale clinical trials are outstanding. The results of the ASSESS-2 trials clearly show that Viagra is both a safe and highly effective formulation in the treatment of ED for Thai men,” said Associate Professor Dr. Apichat Kongkanand, an ASSESS primary investigator and a urologist at Chulalongkorn Hospital. "The true value of Viagra will be measured by its enormous impact on the lives of millions of men suffering from ED worldwide, including Thailand.”
The ASSESS results are consistent with the results of clinical studies conducted in the US. Viagra was tested in more than 4,500 men in the US. In 21 clinical trials, which included men with ED that was diagnosed as mild, moderate or complete, the median age of patients was 55. They had a broad range of conditions associated with ED including high blood pressure, high cholesterol levels, diabetes and prostate surgery. Patients had experienced ED for an average of five years prior to entering the clinical trials.
The drug was shown to be effective in approximately 7 out of 10 men overall and was effective across patients with ED attributed to diabetes, spinal cord injury, or psychological causes, among others. Trial results for patients and partners were assessed using questionnaires designed in conjunction with leading academic researchers.
Sildenafil was well-tolerated by patients in the extensive clinical trials; drop out rates were 2.5 percent for patients taking Viagra compared to 2.3 percent of patients taking placebo. The most common side effects of Viagra were headache, facial flushing and indigestion. Viagra should not be used by patients taking nitrates in any form, including the heart medicine nitroglycerin and long-acting nitrates commonly used for chest pain.
Furthermore, Pfizer urges physicians to consider the overall health profile of their patients prior to prescribing any medication. Because ED often is associated with serious medical conditions such as diabetes and hypertension, a medical exam is an essential opportunity to identify potential underlying causes of ED that may themselves require treatment. Medical research shows that ED is associated with many medical conditions, including heart disease, diabetes and depression. Also, since sexual intercourse, like other forms of physical exertion, increases the heart rate as well as the cardiac work load, physicians may wish to assess their patients’ cardiovascular status prior to their resumption of sexual activity or initiation of any treatment for ED. Viagra is not an aphrodisiac.
During his presentation on “Viagra: A Major Medical Advance”, Dr. Marc Gittelman, a distinguished U.S. urologist, highlighted the prevalence of ED and Viagra’s remarkable efficacy profile in treating the condition, noting that “the number of calls and letters that Pfizer researchers have received from men with ED and their partners is unprecedented, demonstrating the importance of an effective treatment for this serious medical condition. As the first oral formulation proven effective and well-tolerated in clinical trials in the treatment of ED, Viagra is certainly a breakthrough medication.”
Taken about an hour before anticipated sexual activity, Viagra is a tablet that works naturally with sexual stimulation. Viagra is effective in most men with erectile dysfunction (ED), the medical term for impotence, which is associated with a broad range of physical or psychological medical conditions.
Discovered and developed by Pfizer, Viagra is the first in a new class of medications known as phosphodiesterase type 5 (PDE-5) inhibitors that improve blood flow to the penis. In clinical trials, Viagra has been demonstrated to restore sexual function in most patients.
“Viagra is a major scientific advance because it effectively treats a medical condition that has a devastating impact on the quality of life of many men and their partners,” said Ms. Beyhan D. Zaim, General Manager, Thailand/Myanmar, Pfizer Pharmaceuticals. “As an innovative therapy for a significant medical need, Viagra underscores Pfizer’s research-based and patient-focused mission.”
Erectile dysfunction is defined as the consistent inability to achieve and/or maintain an erection sufficient for satisfactory sexual activity. It is estimated that over 100 million men worldwide are affected by ED, according to the medical literature available. The prevalence of ED increases with age.
“Because erectile dysfunction is largely misunderstood, Pfizer is working in close cooperation with the medical community, patients and their partners to increase understanding of this serious medical condition,” said Ms. Zaim.
The FDA has indicated that the Government Pharmaceutical Organisation (GPO) be the sole vendor of Viagra, which will be available for purchase strictly through hospitals in Thailand. Viagra requires a prescription from a specialist in one of the four following fields: urology, cardiology, endocrinology, or psychiatry. ED sufferers should also be aware that only Viagra obtained through these legitimate channels can be considered safe for usage. The price of Viagra will be approximately Baht 400 for a 50-mg tablet.
As part of the approval process, the FDA has requested that Pfizer undertake a public information campaign to ensure Viagra is well understood and used properly and safely. Pfizer has pursued these efforts on two levels, seeking to educate both the doctors who are eligible to prescribe the drug as well as the general public.
This educational role is being played by Pfizer-initiated bodies such as the Erectile Dysfunction Advisory Council and Training Thailand (EDACTT) and the Information Centre on Men’s Health (ICMH), which was launched on August 20 to provide accurate information on important issues affecting men’s health, including ED. Other awareness-raising mediums include the creation of a dedicated Thai interactive website.
To date, Viagra has already been approved in 32 markets around the globe, including the US, Australia, Brazil, the European Union, Switzerland, Israel and other nations. The drug is currently being evaluated for approval in many countries, including Chile, Poland, Russia, Singapore, and Malaysia.
Pfizer is a research-based healthcare company with global operations. In 1997, the company reported revenues of US$12.5 billion and plans to invest approximately US$2 billion in research and development in 1998. For further information, please contact: Pongprach Surojnametakul Derrick Bartel Pairoj Pachanapreeda Presko Shandwick (Thailand) Ltd. Tel: 273 8800 Fax: 273 8880 End.

แท็ก Indonesia   thailand   Bangkok   ADVANC   nation   asian  

เว็บไซต์นี้มีการใช้งานคุกกี้ ศึกษารายละเอียดเพิ่มเติมได้ที่ นโยบายความเป็นส่วนตัว และ ข้อตกลงการใช้บริการ รับทราบ